Project Grant R03HL178874
Award Date 9/1/25
Completion Date 8/31/27
Dollars Obligated $231K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Stanford, CA 94305, USA
Similar Awards
- This $125,703 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research investigating the role of the SYNE1-giant gene in atrial cardiomyopathy. The principal investigator is conducting a comprehensive study to understand the mechanisms by which mutations in the SYNE1 gene, which encodes mechanosensitive proteins in the nuclear envelope, contribute to the development of atrial fibrillation and sinus node dysfunction....
- This federal Project Grant award of $174,528, awarded by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to identify novel treatment targets for atrial myopathy, a condition that contributes to atrial fibrillation and associated heart failure, stroke, and mortality. The primary objective is to leverage human cohort data to discover circulating proteins and metabolites linked to both left atrial function and atrial myopathy, using...
- This federal Project Grant award, totaling $249,000.00, was provided by the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) to The University of Texas Southwestern Medical Center in Dallas, TX. The grant supports research to better understand the molecular determinants of atrial fibrillation (AF), a common and serious heart rhythm disorder. The research aims to investigate how the transcription factor TBX5 and the chromatin remodeling protein CHD4...
- This Project Grant award, provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), funds a study to investigate the molecular mechanisms linking atrial cardiopathy to cardiovascular disease outcomes. The $1,657,473 award, granted on September 24, 2025, supports the use of proteomic and genomic methods in two diverse populations - individuals free of clinically recognized cardiovascular disease and patients with recent...
- This federal Project Grant award for $249,000 was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Children's Hospital Medical Center in Cincinnati, Ohio. The grant supports research on the role of the PITX2 transcription factor in regulating left-right asymmetry and its impact on the development of atrial fibrillation (AF), the most common sustained heart rhythm disorder affecting 5% of the U.S. population. The research aims to...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $673,598 to Baylor College of Medicine to conduct research on the role of cardiomyocyte-fibroblast signaling in atrial fibrillation (AF). The goal is to investigate how reduced production of the paracrine signaling molecule calcitonin, miR-31-dependent downregulation of the calcitonin receptor, and activated BMP1 signaling promote atrial remodeling, fibrosis, and AF...
- The National Institutes of Health's National Heart, Lung, and Blood Institute awarded a $464,502 project grant to Tarleton State University under the Cardiovascular Diseases Research program (CFDA 93.837). The grant, awarded on September 1, 2025, will fund the development of an interactive computer model of the left atrium's electrophysiology to study the underlying mechanisms leading to atrial fibrillation. Key objectives include: 1) constructing an anatomically accurate 3D model of the left...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $694,754 to The Washington University to investigate the connections between genotype, molecular/cellular dysfunction, and small molecule treatments for key troponin cardiomyopathy mutations. The 5-year project aims to build a mechanistic understanding of how specific genetic mutations impact contractile function at the molecular, cellular, and tissue levels...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research into the regulation of cardiac atrial contractility and the role of the myosin binding protein MYBP-HL in cardiomyopathy. The $643,843 award to Loyola University of Chicago will fund investigations into the physiological significance and mechanisms by which the amino-terminal region of MYBP-HL regulates cardiac function. The research will also model the...
- This federal Project Grant award for $769,761 from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), supports research into the mechanisms by which obesity leads to atrial fibrillation. The awardee, Weill Medical College of Cornell University, is developing a mouse model of obesity-induced atrial fibrillation to investigate how nicotinamide adenine dinucleotide (NAD+) pathways and the ATF6 endoplasmic reticulum stress pathway...